Study of REGN3500 and Dupilumab in Patients With Asthma
Status:
Completed
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
To assess the effects of REGN3500, dupilumab, and REGN3500 plus dupilumab, compared with
placebo, on changes in inflammatory gene expression signatures in sputum induced after a
bronchial allergen challenge (BAC) in adults with mild allergic asthma, at week 4 after
treatment initiation compared with those at screening.